KAM
ZYNE

Kazazian Asset Management’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Kazazian Asset Management’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-11,703
Closed -$35K – 70
2018
Q4 		$35K Sell
11,703
-7,089
-38% -$38.8K 0.05% 61
2018
Q3 		$153K Hold
18,792
– – 0.14% 84
2018
Q2 		$183K Buy
+18,792
New +$193K 0.17% 77

Other funds holding ZYNE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CCM
Campbell Capital Management Miami, Florida $279M AUM 49.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.5% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return

Kazazian Asset Management's ZYNE Position: Q1 2019 in Review

Kazazian Asset Management sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q1 2019, closing a stake of 11,703 shares — an estimated $35K sold.

Kazazian Asset Management first reported a position in ZYNE in Q2 2018 and held it in 3 quarters. The position peaked at $183K in Q2 2018. 61 funds tracked by Wall St. Rank hold ZYNE as of Q1 2019.

  • Kazazian Asset Management reported no remaining Zynerba Pharmaceuticals, Inc position as of Q1 2019 after selling out during the quarter.
  • Kazazian Asset Management sold 11,703 Zynerba Pharmaceuticals, Inc shares in Q1 2019, an estimated $35K.
  • Kazazian Asset Management first reported a position in Zynerba Pharmaceuticals, Inc in Q2 2018 and held it in 3 quarters.
  • Kazazian Asset Management's Zynerba Pharmaceuticals, Inc position peaked at $183K in Q2 2018.
  • 61 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q1 2019.

Based on Kazazian Asset Management's 13F filing for Q1 2019, filed 15 May 2019.